Alkaline phosphatase (ALP)

Physiological Role

Alkaline phosphatase refers to a family of enzymes that catalyze the hydrolysis of phosphate groups at alkaline pH. They are distributed across several tissues: liver, biliary tract, bone, intestine, and placenta during pregnancy. Blood measurement reflects the combined activity of these sources, with hepatobiliary and bone fractions predominating in adults.

The hepatobiliary isoform is anchored in the membrane of cells lining the biliary canaliculi. It rises when bile flow slows, a phenomenon called cholestasis. The bone fraction is produced by osteoblasts, the cells responsible for bone formation and mineralization. Its circulating level reflects bone remodeling activity. The intestinal fraction, more discreet, varies after meals in individuals with blood types O and B.

Beyond this enzymatic function, alkaline phosphatase is studied for its role in vascular and bone calcification. It cleaves pyrophosphate, a natural inhibitor of mineralization, and thus conditions the balance between solubility and mineral deposition. This dual localization, both bone and vascular, explains why its interpretation benefits from combination with other markers.

Reference Ranges

Depending on the biomarker, Singular ranges are based on a synthesis of nutritional or clinical reference points and longevity research. They do not replace your laboratory's reference values or your healthcare professional's advice.

Biological Significance

Alkaline phosphatase in the optimal range reflects a stable balance between the various tissue sources: liver, biliary tract, and bone remodeling. This is the favorable scenario for a longevity trajectory, associated in prospective cohorts with reduced mortality.

Elevated values may reflect several origins. A predominant hepatobiliary fraction suggests a slowing of bile flow, often read alongside GGT. When GGT rises in parallel, the hepatobiliary share of the signal is the more likely one. When GGT remains in the optimal zone, it is the bone share that dominates, indicating active remodeling. On this side, the association with all-cause mortality is graded: risk rises with the value, without any published threshold that would make it switch.

Very low values are rare but informative. They may reflect insufficient zinc or magnesium intake, the two minerals that make up the enzyme: each monomer carries two zinc ions and one magnesium ion. Hypothyroidism or prolonged malnutrition can also lower the level. A genetic form called hypophosphatasia, rarer, is characterized by sustained reduced enzymatic activity.

The most refined reading combines alkaline phosphatase with ALT, GGT, vitamin D, and key minerals. It is this cross-reading that allows distinguishing a hepatic origin from a bone origin and directing follow-up toward the relevant axes. The trend over time matters more than an isolated value.

Influencing Factors

Diet. Zinc and magnesium intake directly conditions alkaline phosphatase activity, as both minerals are constituents of the enzyme: each monomer carries two zinc ions and one magnesium ion. The relationship with vitamin B6 runs the other way: it is alkaline phosphatase that dephosphorylates PLP, the circulating form of the vitamin, and not vitamin B6 intake that sets the enzyme. A diet low in protein or chronically restrictive tends to reduce the level.

Fat-soluble vitamins. Vitamin D and vitamin K2 influence alkaline phosphatase through the bone pathway. Vitamin D modulates osteoblast activity, and vitamin K2 directs mineralization toward bone tissue rather than vascular tissue. Vitamin D and vitamin K contribute to the maintenance of normal bones.

Genetics. Polymorphisms of the ALPL gene, which encodes the tissue-nonspecific isoform of the enzyme, modulate the baseline level. The most pronounced forms of these variations correspond to hypophosphatasia, a rare condition characterized by sustained low enzymatic activity.

Medications. Some anticonvulsants and certain antibiotics raise values through enzyme induction, whereas estrogens and oral contraceptives lower them. Long-term corticosteroids also influence bone remodeling and thus the bone fraction. Bone antiresorptive medicines, such as bisphosphonates and denosumab, markedly lower alkaline phosphatase: this is one of the most frequent acquired causes of a low value in adults. Any supplementation or medication should be reported during interpretation.

Life cycle. Pregnancy raises alkaline phosphatase due to the appearance of the placental isoform, particularly in the third trimester. Bone growth during adolescence naturally increases the level, which remains higher than in adults until skeletal maturation is complete.

Blood type and dietary habits. Individuals with blood types O and B have a more pronounced intestinal fraction, particularly after fat-rich meals. This variation is physiological and is not associated with increased risk.

Physical activity. Regular exercise, particularly weight-bearing activities, stimulates bone remodeling and can transiently raise the bone fraction of alkaline phosphatase. This effect is transient and concerns the response to exercise, not the marker's usual level.

In the Singular Formula

Alkaline phosphatase plays a particular role in the Singular formulation engine: it conditions the interpretation of vitamin B6 status. It also enters as a condition in a methylation rule that calibrates vitamins B9 and B12. This enzyme participates in the metabolism of PLP, the active form of B6 measured in blood. An alkaline phosphatase that is too high or too low makes the PLP reading less reliable.

When alkaline phosphatase falls into the very low zone, the engine caps vitamin B6 at its lowest level. This ceiling bounds an intake decided by another rule; on its own, it adds no vitamin B6. This logic reflects the uncertainty linked to a B6 status that is difficult to interpret in this context. When alkaline phosphatase falls into the very high zone and PLP appears low or very low, the situation is analogous. The engine then applies a maintenance dose rather than reinforced supplementation. The combined reading avoids over-supplementing based on a biased PLP.

Two bioactives in the formula are tied to this marker by their membership in the enzyme itself: zinc and magnesium, of which each alkaline phosphatase monomer carries two ions and one ion respectively. They are part of the Singular formula, and their dosage is not adjusted according to alkaline phosphatase.

Alkaline phosphatase completes the liver panel formed with ALT and GGT. These three markers are measured in the same panel, which clarifies the hepatic and the bone share of the signal. No rule of the engine links them, however: alkaline phosphatase acts on vitamin B6, with PLP and albumin.

Scientific Studies

Frequently Asked Questions